RT Journal Article
SR Electronic
T1 Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.05.23284180
DO 10.1101/2023.01.05.23284180
A1 Chen, Wenmei
A1 Xu, Honggang
A1 Hong, Lei
A1 Yang, Ran
A1 Peng, Caiqiu
A1 Wang, Guiqiang
A1 Li, Wei
YR 2023
UL http://medrxiv.org/content/early/2023/01/06/2023.01.05.23284180.abstract
AB Background There is a lack of data on the efficacy of oral Azvudine in Coronavirus Disease treatment. This study aimed to assess the association between Azvudine treatment and clinical outcomes in a cohort of patients infected with the SARS-CoV-2 Omicron variant.Methods This is a retrospective study conducted in two mobile cabin hospitals. All consecutive patients with a diagnosis of COVID-19 admitted from August to October 2022 were included in the study. Linear regression models and Cox proportional hazards models were used to assess the association between Azvudine treatment and time to obtain the first negative nucleic acid test results.Results A total of 207 patients were analyzed, of whom 166 patients (80.2%) received Azvudine treatment after hospitalization, and the rest did not. Linear regression models showed that Azvudine treatment was associated with reduced time to obtain the first negative nucleic acid test results after adjusting for age and gender [mean difference = −1.658; 95% CI: −2.772 to −0.544, P = 0.0039]. The multivariable Cox analysis conforms to the results from the linear regression model (hazard ratio = 1.461; 95% CI: 1.01 to 2.11, P = 0.044).Conclusion Azvudine treatment was associated with reduced virus shedding time. Further studies are needed to confirm our findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by COVID-19 Emergency Project of the Ministry of Science and Technology (2020YFC0846800) and Science Research Project of Bengbu Medical College (KJ2021A0791).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of the First Affiliated Hospital of Bengbu Medical College with a waiver of consent for the the retrospective observational design (No. 2020KY112, 2020KY016).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets are not publicly available due to privacy but are available from the corresponding author on reasonable request.